NASDAQ:QDEL

Quidel Competitors

$108.60
-3.90 (-3.47 %)
(As of 05/6/2021 03:59 PM ET)
Add
Compare
Today's Range
$107.66
$113.50
50-Day Range
$104.79
$142.80
52-Week Range
$104.40
$306.72
Volume46,380 shs
Average Volume954,476 shs
Market Capitalization$4.62 billion
P/E Ratio12.75
Dividend YieldN/A
Beta0.45

Competitors

Quidel (NASDAQ:QDEL) Vs. ALGN, WST, COO, XRAY, STAA, and NEOG

Should you be buying QDEL stock or one of its competitors? Companies in the sub-industry of "health care supplies" are considered alternatives and competitors to Quidel, including Align Technology (ALGN), West Pharmaceutical Services (WST), The Cooper Companies (COO), DENTSPLY SIRONA (XRAY), STAAR Surgical (STAA), and Neogen (NEOG).

Quidel (NASDAQ:QDEL) and Align Technology (NASDAQ:ALGN) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, dividends and valuation.

Insider & Institutional Ownership

84.0% of Quidel shares are owned by institutional investors. Comparatively, 85.8% of Align Technology shares are owned by institutional investors. 14.1% of Quidel shares are owned by insiders. Comparatively, 1.2% of Align Technology shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Quidel and Align Technology, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Quidel10302.50
Align Technology111002.75

Quidel currently has a consensus price target of $189.00, suggesting a potential upside of 74.03%. Align Technology has a consensus price target of $627.0909, suggesting a potential upside of 7.25%. Given Quidel's higher possible upside, analysts plainly believe Quidel is more favorable than Align Technology.

Profitability

This table compares Quidel and Align Technology's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Quidel36.91%63.31%40.55%
Align Technology76.00%68.99%46.64%

Volatility and Risk

Quidel has a beta of 0.45, indicating that its share price is 55% less volatile than the S&P 500. Comparatively, Align Technology has a beta of 1.68, indicating that its share price is 68% more volatile than the S&P 500.

Earnings and Valuation

This table compares Quidel and Align Technology's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Quidel$534.89 million8.64$72.92 million$2.7339.78
Align Technology$2.41 billion19.23$442.78 million$4.96117.89

Align Technology has higher revenue and earnings than Quidel. Quidel is trading at a lower price-to-earnings ratio than Align Technology, indicating that it is currently the more affordable of the two stocks.

Summary

Align Technology beats Quidel on 12 of the 14 factors compared between the two stocks.

Quidel (NASDAQ:QDEL) and West Pharmaceutical Services (NYSE:WST) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, valuation, risk and profitability.

Earnings & Valuation

This table compares Quidel and West Pharmaceutical Services' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Quidel$534.89 million8.64$72.92 million$2.7339.78
West Pharmaceutical Services$1.84 billion13.20$241.70 million$3.24101.52

West Pharmaceutical Services has higher revenue and earnings than Quidel. Quidel is trading at a lower price-to-earnings ratio than West Pharmaceutical Services, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Quidel has a beta of 0.45, indicating that its stock price is 55% less volatile than the S&P 500. Comparatively, West Pharmaceutical Services has a beta of 1.13, indicating that its stock price is 13% more volatile than the S&P 500.

Profitability

This table compares Quidel and West Pharmaceutical Services' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Quidel36.91%63.31%40.55%
West Pharmaceutical Services14.69%19.01%12.78%

Analyst Ratings

This is a breakdown of recent ratings and target prices for Quidel and West Pharmaceutical Services, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Quidel10302.50
West Pharmaceutical Services01202.67

Quidel currently has a consensus price target of $189.00, indicating a potential upside of 74.03%. West Pharmaceutical Services has a consensus price target of $310.00, indicating a potential downside of 5.76%. Given Quidel's higher possible upside, analysts clearly believe Quidel is more favorable than West Pharmaceutical Services.

Institutional and Insider Ownership

84.0% of Quidel shares are owned by institutional investors. Comparatively, 92.6% of West Pharmaceutical Services shares are owned by institutional investors. 14.1% of Quidel shares are owned by company insiders. Comparatively, 1.6% of West Pharmaceutical Services shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

West Pharmaceutical Services beats Quidel on 8 of the 14 factors compared between the two stocks.

Quidel (NASDAQ:QDEL) and The Cooper Companies (NYSE:COO) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, earnings, dividends, valuation, risk and institutional ownership.

Analyst Recommendations

This is a breakdown of current recommendations for Quidel and The Cooper Companies, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Quidel10302.50
The Cooper Companies04702.64

Quidel currently has a consensus target price of $189.00, indicating a potential upside of 74.03%. The Cooper Companies has a consensus target price of $385.50, indicating a potential downside of 4.88%. Given Quidel's higher possible upside, research analysts plainly believe Quidel is more favorable than The Cooper Companies.

Valuation and Earnings

This table compares Quidel and The Cooper Companies' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Quidel$534.89 million8.64$72.92 million$2.7339.78
The Cooper Companies$2.43 billion8.20$238.40 million$9.6442.06

The Cooper Companies has higher revenue and earnings than Quidel. Quidel is trading at a lower price-to-earnings ratio than The Cooper Companies, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Quidel and The Cooper Companies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Quidel36.91%63.31%40.55%
The Cooper Companies9.81%12.79%7.20%

Volatility and Risk

Quidel has a beta of 0.45, indicating that its share price is 55% less volatile than the S&P 500. Comparatively, The Cooper Companies has a beta of 0.82, indicating that its share price is 18% less volatile than the S&P 500.

Insider & Institutional Ownership

84.0% of Quidel shares are owned by institutional investors. Comparatively, 95.8% of The Cooper Companies shares are owned by institutional investors. 14.1% of Quidel shares are owned by insiders. Comparatively, 1.4% of The Cooper Companies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

The Cooper Companies beats Quidel on 8 of the 14 factors compared between the two stocks.

DENTSPLY SIRONA (NASDAQ:XRAY) and Quidel (NASDAQ:QDEL) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, earnings, risk, institutional ownership, dividends and valuation.

Risk & Volatility

DENTSPLY SIRONA has a beta of 0.98, meaning that its stock price is 2% less volatile than the S&P 500. Comparatively, Quidel has a beta of 0.45, meaning that its stock price is 55% less volatile than the S&P 500.

Profitability

This table compares DENTSPLY SIRONA and Quidel's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
DENTSPLY SIRONA-1.40%7.13%4.13%
Quidel36.91%63.31%40.55%

Analyst Ratings

This is a summary of current ratings for DENTSPLY SIRONA and Quidel, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
DENTSPLY SIRONA15602.42
Quidel10302.50

DENTSPLY SIRONA currently has a consensus price target of $56.2727, indicating a potential downside of 16.53%. Quidel has a consensus price target of $189.00, indicating a potential upside of 74.03%. Given Quidel's stronger consensus rating and higher possible upside, analysts clearly believe Quidel is more favorable than DENTSPLY SIRONA.

Earnings & Valuation

This table compares DENTSPLY SIRONA and Quidel's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
DENTSPLY SIRONA$4.03 billion3.65$262.90 million$2.4527.52
Quidel$534.89 million8.64$72.92 million$2.7339.78

DENTSPLY SIRONA has higher revenue and earnings than Quidel. DENTSPLY SIRONA is trading at a lower price-to-earnings ratio than Quidel, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

96.0% of DENTSPLY SIRONA shares are owned by institutional investors. Comparatively, 84.0% of Quidel shares are owned by institutional investors. 0.5% of DENTSPLY SIRONA shares are owned by insiders. Comparatively, 14.1% of Quidel shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Quidel beats DENTSPLY SIRONA on 9 of the 14 factors compared between the two stocks.

Quidel (NASDAQ:QDEL) and STAAR Surgical (NASDAQ:STAA) are both mid-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, risk, profitability, analyst recommendations and institutional ownership.

Profitability

This table compares Quidel and STAAR Surgical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Quidel36.91%63.31%40.55%
STAAR Surgical5.73%8.99%7.12%

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Quidel and STAAR Surgical, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Quidel10302.50
STAAR Surgical03302.50

Quidel presently has a consensus price target of $189.00, indicating a potential upside of 74.03%. STAAR Surgical has a consensus price target of $72.1667, indicating a potential downside of 45.52%. Given Quidel's higher possible upside, analysts clearly believe Quidel is more favorable than STAAR Surgical.

Valuation & Earnings

This table compares Quidel and STAAR Surgical's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Quidel$534.89 million8.64$72.92 million$2.7339.78
STAAR Surgical$150.18 million41.36$14.05 million$0.46287.96

Quidel has higher revenue and earnings than STAAR Surgical. Quidel is trading at a lower price-to-earnings ratio than STAAR Surgical, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

84.0% of Quidel shares are owned by institutional investors. Comparatively, 85.4% of STAAR Surgical shares are owned by institutional investors. 14.1% of Quidel shares are owned by company insiders. Comparatively, 3.9% of STAAR Surgical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Volatility & Risk

Quidel has a beta of 0.45, suggesting that its stock price is 55% less volatile than the S&P 500. Comparatively, STAAR Surgical has a beta of 1.09, suggesting that its stock price is 9% more volatile than the S&P 500.

Summary

Quidel beats STAAR Surgical on 8 of the 12 factors compared between the two stocks.

Neogen (NASDAQ:NEOG) and Quidel (NASDAQ:QDEL) are both mid-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, valuation, profitability, analyst recommendations, institutional ownership and dividends.

Profitability

This table compares Neogen and Quidel's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Neogen13.92%8.13%7.45%
Quidel36.91%63.31%40.55%

Risk and Volatility

Neogen has a beta of 0.5, indicating that its share price is 50% less volatile than the S&P 500. Comparatively, Quidel has a beta of 0.45, indicating that its share price is 55% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Neogen and Quidel, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Neogen02102.33
Quidel10302.50

Neogen presently has a consensus target price of $81.50, suggesting a potential downside of 13.89%. Quidel has a consensus target price of $189.00, suggesting a potential upside of 74.03%. Given Quidel's stronger consensus rating and higher possible upside, analysts plainly believe Quidel is more favorable than Neogen.

Institutional & Insider Ownership

92.8% of Neogen shares are owned by institutional investors. Comparatively, 84.0% of Quidel shares are owned by institutional investors. 0.9% of Neogen shares are owned by company insiders. Comparatively, 14.1% of Quidel shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Neogen and Quidel's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Neogen$418.17 million12.11$59.47 million$1.1383.76
Quidel$534.89 million8.64$72.92 million$2.7339.78

Quidel has higher revenue and earnings than Neogen. Quidel is trading at a lower price-to-earnings ratio than Neogen, indicating that it is currently the more affordable of the two stocks.

Summary

Quidel beats Neogen on 10 of the 14 factors compared between the two stocks.

Ad All Marijuana Stocks
Could This Seattle Pot Stock SOAR as Legal Weed Market Expands?
Fifteen states plus the District of Columbia now permit the recreational use of cannabis and Congress is on track to decriminalize marijuana possession on the federal level. As a result, the North American cannabis market is expected to TRIPLE in size from $30 billion to $100 billion by the year 2027 – and one Seattle manufacturer is poised to cash in!

Quidel Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Align Technology logo
ALGN
Align Technology
1.9$584.72-2.6%$45.05 billion$2.41 billion26.60Analyst Report
West Pharmaceutical Services logo
WST
West Pharmaceutical Services
1.9$328.94-0.1%$24.27 billion$1.84 billion86.79Earnings Announcement
Dividend Announcement
Analyst Revision
The Cooper Companies logo
COO
The Cooper Companies
1.9$405.50-1.1%$19.70 billion$2.43 billion84.30Analyst Report
DENTSPLY SIRONA logo
XRAY
DENTSPLY SIRONA
2.0$67.42-0.3%$14.75 billion$4.03 billion-293.13Earnings Announcement
Analyst Report
Unusual Options Activity
News Coverage
STAAR Surgical logo
STAA
STAAR Surgical
1.4$132.46-5.8%$5.85 billion$150.18 million697.19Earnings Announcement
Analyst Upgrade
News Coverage
Gap Up
Neogen logo
NEOG
Neogen
1.2$94.65-1.2%$5.01 billion$418.17 million83.03
ICU Medical logo
ICUI
ICU Medical
1.5$211.65-0.6%$4.46 billion$1.27 billion55.99Insider Selling
Merit Medical Systems logo
MMSI
Merit Medical Systems
1.5$64.90-1.9%$3.54 billion$994.85 million-122.45Earnings Announcement
Analyst Report
Insider Selling
Analyst Revision
Haemonetics logo
HAE
Haemonetics
2.1$61.44-1.1%$3.16 billion$988.48 million29.68Upcoming Earnings
Analyst Downgrade
Increase in Short Interest
Atrion logo
ATRI
Atrion
1.1$604.80-0.5%$1.10 billion$155.07 million34.07Gap Up
Cerus logo
CERS
Cerus
1.7$5.95-1.2%$1.03 billion$74.65 million-15.26Earnings Announcement
Unusual Options Activity
News Coverage
Meridian Bioscience logo
VIVO
Meridian Bioscience
1.7$19.18-0.3%$830.11 million$253.67 million17.76Upcoming Earnings
OraSure Technologies logo
OSUR
OraSure Technologies
1.7$9.61-6.1%$648.95 million$154.60 million-41.78Earnings Announcement
Analyst Report
News Coverage
Antares Pharma logo
ATRS
Antares Pharma
1.8$3.61-5.0%$639.74 million$123.86 million60.18Analyst Upgrade
News Coverage
Anika Therapeutics logo
ANIK
Anika Therapeutics
1.5$40.83-1.5%$595.23 million$114.51 million-86.87Analyst Upgrade
Utah Medical Products logo
UTMD
Utah Medical Products
0.9$87.85-0.7%$320.30 million$46.90 million27.71
This page was last updated on 5/6/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.